Reference priceJPY ¥91,875.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Tukysa |
|---|---|
| Manufacturer | Pfizer Pharma GmbH |
| Prescription required | Yes |
Tukysa 150mg Filmtabletten,84St x 1(Tucatinib)
Tucatinib
Description
Tukysa 150mg Filmtabletten,84St x 1(Tucatinib) is a medicine catalog record in the MediPriceHub database. Active ingredient: Tucatinib. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Pfizer Pharma GmbH. Therapeutic category: Medicine Library > Oncology Medicines > Breast Cancer Drugs. Pack information: 150 84. Origin country or market: Germany. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
TUKYSA is a kinase inhibitor indicated: • in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. • in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.How to Use
Use Tucatinib under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: Tucatinib. Pack size: 150 84. Pack unit: box. Manufacturer: Pfizer Pharma GmbH. Origin country: Germany. Source category: Medicine Library > Oncology Medicines > Breast Cancer Drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.この情報は参考情報です。医薬品を使用する前に医療専門家へご相談ください。